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Methods: We examined five methods for determining cut points.
Results: The reliable worsening method produced a cut point only for amyloid PET. The specificity,
sensitivity, and accuracy of cognitively impaired versus young clinically normal (CN) methods
labeled the most people abnormal and all gave similar cut points for tau PET, FDG PET, and cortical
thickness. Cut points defined using the accuracy of cognitively impaired versus age-matched CN
method labeled fewer people abnormal.
Discussion: In the future, we will use a single cut point for amyloid PET (standardized uptake value
ratio, 1.42; centiloid, 19) based on the reliable worsening cut point method. We will base lenient cut
points for tau PET, FDG PET, and cortical thickness on the accuracy of cognitively impaired versus
young CN method and base conservative cut points on the accuracy of cognitively impaired versus
age-matched CN method.
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Imaging and biofluid biomarkers of Alzheimer’s disease
(AD) are increasingly important to the study of brain aging
and dementia. Although every biomarker exists on a contin-
uum, dichotomizing biomarker values is necessary in certainthor. Tel.: 507-284-7096; Fax: 507-284-9778.
ck.clifford@mayo.edu
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he Authors. Published by Elsevier Inc. on behalf of the Alzhe
commons.org/licenses/by-nc-nd/4.0/).situations. Clinical trials require a normal/abnormal classifi-
cation when a biomarker is used to determine eligibility
[1,2]. Additionally, modern criteria for AD across the
cognitive spectrum label an individual’s biomarker as
normal or abnormal [3–7]. The goal of our study was to
develop amyloid positron emission tomography (PET), tau
PET, flouro-deoxyglucose (FDG) PET, and structural mag-
netic resonance imaging (MRI) biomarker cut points.
In brain aging and dementia research, defining a normal/
abnormal cut point for quantitative amyloid PET has receivedimer’s Association. This is an open access article under the CC BY-NC-ND
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including the 10th percentile of clinically diagnosed AD
dementia [16]. We adopted this last approach in 2012 [16] for
amyloid PET, FDG PET, and structural MRI with the assump-
tion that the samemethod should be used to select cut points for
all biomarkers. However, we now believe that it may be appro-
priate to select cut points for different AD biomarkers using
differentmethods. In particular, it seems reasonable to treat am-
yloid biomarkers differently from others. Defining cut points
using individuals that meet certain clinical criteria without re-
gard to evidence of amyloidosis is problematic [17]. The field
has reached a consensus that biomarker evidence of amyloid-
osis is necessary for an accurate diagnosis of AD in living per-
sons [3,4,6]. Of individuals with clinically diagnosed AD
dementia, 10%–30% do not have AD at autopsy [18] or have
no biomarker evidence of amyloidosis [19,20]. Therefore,
using a clinical diagnosis of AD dementia to define an
“affected” group of cases with AD when selecting biomarker
cut points has significant inherent error. Similarly, around
30% of clinically normal elderly individuals have AD at
autopsy [21] or have biomarker evidence of amyloidosis [22–
24], and therefore, a clinically defined “unaffected” non-AD
control group also has significant inherent error [17].
Tau PET has recently been introduced [25–34], and
defining a normal/abnormal cut point is needed to place this
modality on the same footing with other AD biomarkers.
This in turn provides an opportunity to revisit the issue of
defining cut points for more established imaging biomarkers
used in AD research. Our objective was to examine different
methods for defining cut points for amyloid PET, structural
MRI, FDG PET, and tau PET. Identifying a single “best” cut
point for each biomarker would provide the most
straightforward outcome. However, “best” depends on the
context of use [35], and therefore, it is reasonable that different
cut points might apply for a given biomarker when used for
different purposes [36].
In practice, biomarkers vary in terms of whether numeri-
cally high or low values are more abnormal. To simplify
our presentation, we have reversed the axes for FDG PET
and cortical thickness so that from left to right or bottom to
top values are increasingly abnormal. In our general discus-
sion of biomarkers, we treat higher values as more abnormal.2. Methods
2.1. Participants
All clinically normal (CN) individuals in this study were
participants enrolled in the Mayo Clinic Study of Aging
(MCSA) [37]. Individuals with mild cognitive impairment
(MCI) or AD dementia were participants enrolled in either
the MCSA or the Mayo Alzheimer’s Disease Research Cen-
ter (ADRC). Beginning in 2004, theMCSA enrolled individ-
uals aged 70–89 years; in 2012, the MCSA began enrolling
individuals 501 years; and, in 2015, the MCSA began
enrolling individuals 301 years. From 2006 to 2015, the im-aging battery consisted of MRI, FDG PET, and amyloid
PET. In 2015, tau PET was added to this battery, and FDG
PET became optional.
All individuals included in this study completed MRI and
amyloid PET imaging. However, owing to changes in the
MCSA enrollment protocol, not all completed tau PET and
FDG PET. Because of its recent introduction, only 508 indi-
viduals have tau PET scans. To take advantage of all avail-
able data, we created two separate samples for our
analyses. The first sample included all individuals with tau
PET, amyloid PET, and MRI (many of whom also had
FDG PET). We refer to this sample as the “tau/amyloid/
MRI sample.” The second sample included all individuals
with amyloid PET, FDG PET, andMRI.We refer to this sam-
ple as the “amyloid/FDG/MRI sample.” Some of these indi-
viduals also had tau PET imaging. If individuals had
multiple imaging visits, we used the first available visit
with the necessary modalities.
The evolution of the MCSA described above has several
practical implications. First, there are relatively few individ-
uals under age 50 years. As the start of tau PET scanning
coincided with enrolling this younger age group, all who
consented to imaging had tau PET, amyloid PET, and
MRI. Second, serial imaging data are only available in indi-
viduals age 50 years or older and only available for amyloid
PET, FDG PET, and MRI.2.2. Standard protocol approvals, registrations, and
patient consents
These studies were approved by the Mayo Clinic and
Olmsted Medical Center institutional review boards and
written informed consent was obtained from all participants.2.3. Experimental design2.3.1. Imaging methods
Amyloid PET imaging was performed with Pittsburgh
Compound B [38] and tau PET with AV1451 [29].
Computed tomography was obtained for attenuation correc-
tion. Late uptake amyloid PET images were acquired from
40–60 minutes, FDG from 30–40 minutes, and tau PET
from 80–100 minutes after injection. PET images were
analyzed with our in-house fully automated image process-
ing pipeline [39], where image voxel values are extracted
from automatically labeled regions of interest (ROIs) prop-
agated from anMRI template. An amyloid PET standardized
uptake value ratio (SUVR) was formed from the voxel-
number weighted average of the median uptake in the pre-
frontal, orbitofrontal, parietal, temporal, anterior and poste-
rior cingulate, and precuneus ROIs normalized to the
cerebellar crus gray median. Amyloid PET values are ex-
pressed both in SUVR units and in centiloid units. The
SUVR to centiloid conversion was done as recommended
in Klunk et al [40]. An AD-signature FDG PET composite
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average of the median uptake in the angular gyrus, posterior
cingulate, and inferior temporal cortical ROIs and normal-
ized to the pons and vermis median [41]. A tau PET meta-
ROI was formed from a voxel-number weighted average
of the median uptake in the entorhinal, amygdala, parahip-
pocampal, fusiform, inferior temporal, and middle temporal
ROIs normalized to the cerebellar crus gray median. PET
data were not partial volume corrected. However, the data
were “sharpened”—that is, voxels whose probability of be-
ing cerebrospinal fluid (CSF) was greater than the probabil-
ity of being gray matter and greater than the probability of
being white matter were discarded from all PET ROI mea-
sures.
MRI was performed on one of three 3T GE systems. The
MRI measure was a FreeSurfer (v5.3)-derived AD-signature
meta-ROI composed of the surface-area weighted average
of the mean cortical thickness in the following individual
ROIs: entorhinal, inferior temporal, middle temporal, and
fusiform.2.4. Statistical analysis2.4.1. Methods of defining cut points
We used five methods for determining biomarker cut
points which we term (1) reliable worsening, (2) specificity,
(3) sensitivity, (4) accuracy of cognitively impaired versus
younger CN, and (5) accuracy of cognitively impairedFig. 1. Cut point methods. Graphical summary of the five methods used for determ
correspond to biomarker worsening. A biomarker’s cumulative distribution functi
portion of observations x on the vertical axis.versus age-matched CN. We summarize the five methods
graphically in Fig. 1 and describe the methodology in detail
below.
The reliable worsening cut point was based on identifying
a threshold baseline value beyond which the rate of change
in that biomarker worsens reliably. With this method, we
first estimated the annual rate of change in each biomarker
within each individual with serial imaging data using linear
regression. Next, a nonparametric scatter plot smoother was
used to plot the mean rate of change in biomarker on the y-
axis versus the baseline biomarker value on the x-axis [42].
We then identified the biomarker value that corresponded to
the minimum point on this rate versus baseline curve.
Although the minimum corresponds to a threshold beyond
which the biomarker rate of change can be expected to in-
crease on average, we obtained a more conservative, or reli-
able, cut point by projecting the upper bound of a 50%
prediction interval at the minimum rightward until it inter-
sected the rate versus baseline curve. The point of this inter-
section defined a reliable worsening cut point. Because we
do not yet have longitudinal tau PET data, this reliable wors-
ening analysis was only applicable to MRI, amyloid, and
FDG PET and, as shown in results, produced a result only
for amyloid PET. Individuals used in this analysis included
all MCSA participants (CN, MCI, and AD dementia) with
at least one follow-up imaging study.
The specificity-based cut point corresponded to the 95th
percentile of the biomarker distribution amongMCSACN in-
dividuals’ aged 30–49 years, all of whom had normal amyloidining cut points. In each panel, increasing numeric values of the biomarker
on (CDF) indicates a biomarker value x on the horizontal axis and the pro-
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ously. As noted previously, we treat all biomarkers such
that the 95th percentile corresponds to more abnormal values.
The rationale for a specificity-based cut point is that young in-
dividuals are likely to be relatively free of AD pathology. This
approach is commonly used in laboratory medicine [43]. This
approach was applicable to all four imaging methods.
Because of limited sample sizes among those with tau PET,
we estimated the 95th percentile based on calculating a
smoothed cumulative distribution function (CDF) from a
kernel density estimate of the distribution. This can be inter-
preted as a smoothed empirical CDF.
The sensitivity-based cut point corresponded to the 10th
percentile of the biomarker distribution among cognitively
impaired (aMCI or AD) individuals from the MCSA or
ADRC aged 60 years or older who had abnormal amyloid,
where the definition of abnormal amyloid was based on
the reliable worsening cut point described above. The 10th
percentile (i.e., 90% sensitivity) in this impaired group
was calculated using the same CDF approach described
above. This method is very similar to our earlier approach
from 2012 [16]. However, this updated method only
included people with abnormal amyloid so that the cogni-
tively impaired group was not contaminated with individuals
who are not in the AD pathway [17]. This sensitivity-based
cut point is only applicable to selecting the cut point for
MRI, FDG PET, and tau PET because the impaired group
was required to have elevated values of amyloid PET.
The fourth method was based on discriminating between
the cognitively impaired individuals used in the sensitivity
cut point analysis and younger CN individuals used in the
specificity cut point analysis. This case/control discrimina-
tion cut point was obtained by identifying the point of
maximum separation between the smoothed CDFs of the
two groups. This is equivalent to maximizing accuracy,
defined as sensitivity 2 (1 2 specificity). This method is
only applicable to selecting cut points for MRI, FDG PET,
and tau PET because the cognitively impaired individuals
were required to have elevated amyloidosis.
The fifth method was also based on discriminating be-
tween cognitively impaired and CN individuals. However,
in contrast to the fourth method, the control group consisted
of older CN individuals with normal amyloid from the
MCSAwho were age and sex matched to the impaired group.
Using a control group with similar ages as the cognitively
impaired group allows this cut point to focus on AD-related
differences between the groups as opposed to both AD-
specific and nonspecific age-related differences. Requiring
the CN individuals to have normal amyloid insures that con-
trols are not in the AD pathway. This method is only appli-
cable to selecting cut points for MRI, FDG PET, and tau
PET because amyloid PET was used to define both groups.
2.4.2. Methods for evaluating cut points
To evaluate the utility of cut points defined from the
different methods above, we estimated the proportion ofMCSA CN individuals with abnormal biomarker values by
age using logistic regression models. Age was fit with a
restricted cubic spline with knots at ages 50, 65, and 80
years. We also generated histograms of the biomarkers
among all MCSA individuals aged 50–89 years to illustrate
where the cut points fall in the biomarker distributions
within a population. These histograms were weighted to
reflect the age/sex frequencies in Olmsted County.3. Results
Characteristics of the clinical groups used are found in
Table 1, where we distinguish between the two samples in
our study. Supplementary Fig. 1 illustrates how the clinical
groups within the tau/amyloid/MRI sample compare to the
clinical groups in the amyloid/FDG/MRI sample.
Fig. 2 shows the relationship between the annual rate of
change and baseline biomarker for amyloid PET, FDG PET,
and cortical thickness among all MCSA individuals with se-
rial imaging. Tau PET is not shown because we only have
cross-sectional data currently. Using this reliable worsening
method, we defined the amyloid PET cut point as 1.42
SUVR, corresponding to a centiloid value of 19. A reliable
worsening cut point could not be determined for FDG or
cortical thickness because the rate of change was not signifi-
cantly associated with the baseline biomarker values.
Fig. 3 shows the estimated cumulative distribution function
among younger CN individuals, cognitively impaired individ-
uals, and age-matched and sex-matched CN individuals. The
specificity, sensitivity, and accuracy of impaired versus
younger CN methods gave very similar cut points within
each biomarker: 1.21, 1.20, and 1.23 SUVR for tau PET,
respectively; 1.53, 1.56, and 1.56 SUVR for FDG PET; and
2.69, 2.70, and 2.67 mm for cortical thickness. However, cut
points defined using the accuracy of impaired versus age-
matched CN method were always more conservative (1.33
SUVR for tau PET, 1.41 SUVR for FDG PET, and 2.57 mm
for cortical thickness). Although a cut point for amyloid
PET could not be determined using the sensitivity or accuracy
methods due to circularity in group definitions, the specificity
method produced a cut point of 1.30 SUVR, centiloid 8.
In Fig. 4, we illustrate the continuous distribution of am-
yloid PET, tau PET, FDG PET, and MRI cortical thickness
values versus age among all MCSACNwith horizontal lines
representing the cut points from each method. A box plot of
values among impaired individuals is included in the plot of
each biomarker for reference.
Fig. 4 also shows the estimated proportion of CN that are
labeled abnormal by age for each of the five cut point methods.
For tau PET, the cut point from the sensitivity method labeled
the most people abnormal, whereas the specificity and accu-
racy of impaired versus young CN methods labeled about
10% and 15% fewer people abnormal, respectively. For
FDG PET, the sensitivity and accuracy of impaired versus
young CN methods (which produced the same cut point)
labeled the most people abnormal, whereas the specificity
Table 1
Characteristics of participant samples used in analyses
Characteristic
Tau/amyloid/MRI sample Amyloid/FDG/MRI sample
Cut point definition samples Cut point evaluation samples Cut point definition samples Cut point evaluation samples
Young CN
(n 5 49)
Matched CN
(n 5 102)*
Cognitively
impaired
(n 5 51)y
All CN
(n 5 438)
MCSA 50–89
(n 5 417)z
Matched CN
(n 5 214)*
Cognitively
impaired
(n 5 214)y
MCSA serial
(n 5 682)x
All CN
(n 5 1503)
MCSA 50–89
(n 5 1646)z
Age, years
Median (IQR) 39 (34–44) 73 (67–78) 74 (67–79) 69 (59–78) 71 (64–79) 77 (72–84) 77 (72–84) 75 (68–80) 71 (63–78) 72 (64–79)
Min, max 30–48 60–90 60–88 30–94 52–89 60–93 60–93 51–94 30–95 50–89
Male gender, no. (%) 28 (57%) 70 (69%) 35 (69%) 241 (55%) 236 (57%) 124 (58%) 124 (58%) 399 (59%) 790 (53%) 882 (54%)
Education, years,
Median (IQR)
16 (14–16) 14 (13–17) 16 (12–16) 16 (13–17) 15 (13–16) 14 (12–17) 15 (12–16) 14 (12–16) 15 (12–16) 14 (12–16)
APOE ε4 positive,
no. (%)
5 (19%) 15 (15%) 33 (72%) 106 (26%) 109 (27%) 29 (14%) 143 (69%) 187 (28%) 392 (27%) 462 (29%)
MMSE, median (IQR) 29 (29–30) 29 (28–29) 24 (22–27) 29 (28–29) 29 (28–29) 28 (27–29) 25 (22–27) 28 (27–29) 29 (28–29) 29 (27–29)
Tau PET, SUVR,
median (IQR)
1.12 (1.06–1.14) 1.18 (1.11–1.22) 1.72 (1.37–2.07) 1.18 (1.12–1.23) 1.19 (1.13–1.25)
Amyloid PET, SUVR,
median (IQR)
1.21 (1.17–1.24) 1.32 (1.28–1.37) 2.50 (2.24–2.70) 1.35 (1.27–1.48) 1.36 (1.29–1.53) 1.32 (1.29–1.37) 2.33 (2.00–2.59) 1.36 (1.30–1.54) 1.34 (1.28–1.45) 1.35 (1.29–1.51)
FDG PET, SUVR,
median (IQR)
1.74 (1.65–1.82) 1.54 (1.46–1.64) 1.20 (1.12–1.34) 1.57 (1.47–1.66) 1.54 (1.45–1.64) 1.54 (1.44–1.64) 1.32 (1.23–1.44) 1.55 (1.45–1.65) 1.58 (1.47–1.68) 1.56 (1.45–1.66)
Cortical thickness,
mm, median (IQR)
2.86 (2.78–2.93) 2.70 (2.60–2.79) 2.39 (2.27–2.60) 2.73 (2.63–2.83) 2.70 (2.61–2.80) 2.65 (2.58–2.73) 2.50 (2.35–2.60) 2.67 (2.59–2.77) 2.71 (2.62–2.81) 2.70 (2.60–2.80)
*Thematched CN subgroups include clinically normal individuals from theMCSA aged 60 or older with amyloid PET, 1.42 SUVR and are matched on age (within 3 years) and sex to the cognitively impaired
subgroups. The tau/amyloid/MRI matched CN sample was matched 2 to 1 to the tau/amyloid/MRI cognitively impaired sample. The amyloid/FDG/MRI matched CN sample was matched 1 to 1 to the amyloid/
FDG/MRI cognitively impaired sample.
yThe tau/amyloid/MRI cognitively impaired subgroup includes 19 aMCI and 32 AD dementia individuals with amyloid PET.1.42 SUVR and aged 60 or older. The amyloid/FDG/MRI cognitively impaired
subgroup includes 136 aMCI and 78 AD dementia individuals with amyloid PET .1.42 SUVR and aged 60 or older.
zThe tau/amyloid/MRI MCSA 50–89 subgroup includes 384 CN, 27 MCI, 5 individuals with dementia, and 1 individual with an other diagnosis. The amyloid/FDG/MRI MCSA 50–89 subgroup includes 1446
CN, 186 MCI, 12 individuals with dementia, and 2 individuals with an other diagnosis.
xThe amyloid/FDG/MRI serial imaging subgroup includes 606 CN, 75 MCI, and 1 individual with dementia.
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Fig. 2. Reliable worsening cut point. Scatter plot of annual rate of change in
imaging biomarker versus baseline with a nonparametric scatter plot
smoother line and a 50% prediction interval. For amyloid PET (A), the ar-
rows and solid blue line illustrate how the reliable worsening (RW) cut point
was obtained. For this panel, values are shown in both SUVR and centiloid
units. A reliable worsening cut point was not obtained for FDG PETor MRI
cortical thickness (B and C).
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mance was similar across the three methods for cortical thick-
ness, although the sensitivity method labeled more people
abnormal and the accuracy of impaired versus young CN
fewer by roughly 10%. In contrast, cut points defined using
the accuracy of impaired versus age-matched CN methodlabeled the fewest people abnormal for all biomarkers. For
example, at age 70 years, the proportion of CN-labeled
abnormal using the specificity, sensitivity, accuracy of
impaired versus young CN, and accuracy of impaired versus
age-matched CN methods for tau PET is 33%, 42%, 26%,
and 5%, respectively. For FDG PET, the proportions were
35%, 45%, 45%, and 9%, and for MRI cortical thickness,
the proportions were 37%, 42%, 31%, and 10%, respectively.
For amyloid PET, 30%of CN individuals are labeled abnormal
at age 70 using the reliable worsening cut point, in contrast to
75% using the specificity cut point.
In Fig. 5, we illustrate the histograms of the distribution
of values among all MCSA individuals ages 50–89 years
along with the cut points selected by the different methods
for each. The histograms have been weighted by age and
sex to reflect the age/sex population frequencies in Olmsted
county. We also show the distribution of a prototypical non-
imaging and non-AD biomarker, systolic blood pressure, to
illustrate how an established biomarker and its accepted cut
point compares with those used in AD research. MRI, FDG
PET, tau PET, and systolic blood pressure are all approxi-
mately normally distributed. The frequency distribution of
amyloid PET is unimodal but has a prominent skew.
Supplementary Fig. 2 illustrates how the proportion of
MCSA CN individuals labeled abnormal by age using the
cut point definitions for amyloid PET, FDG PET, and MRI
cortical thickness defined in this analysis compare to our
previous cut point definitions [44]. Due to changes in the im-
plementations of the biomarker processing pipelines the
exact numeric values reported in this paper are not directly
comparable to previously reported values.4. Discussion
4.1. Cut point selection for amyloid PET
Of the five cut point methods considered, only the reliable
worsening and specificity methods are applicable to amyloid
PET, because amyloid was used in the group definitions for
the other methods. However, the specificity cut point of
SUVR 1.30, centiloid 8, classifies 75% of CN individuals
in the MCSA at age 70 years as above the amyloid threshold.
A cut point indicating most 70-year olds have abnormal am-
yloid is inconsistent with autopsy data which indicate that
the proportion of the population with amyloidosis at age
70 years is just under 40% [45]. In vivo amyloid imaging
significantly underestimates actual b-amyloid load at au-
topsy (Colin Masters, Alzheimer’s Association International
Conference, 2016); therefore, the cut point obtained from
the sensitivity method is not plausible for amyloid PET.
One possible, although speculative, explanation is illustrated
by Fig. 4 where values among individuals with low-amyloid
PET uptake tend to steadily increase with age. We suspect
that nonspecific ligand uptake in the white matter might in-
crease with age. Nonspecific white matter uptake would
bleed into cortical target ROIs. The result would be that
Fig. 3. Specificity, sensitivity, and accuracy cut points. Cumulative distribution function (CDF) plots for young CN individuals (light gray), cognitively
impaired individuals (black), and older CN individuals that were age and sex matched to the cognitively impaired group (dark gray). The arrows indicate
cut points chosen corresponding to 95% specificity (CDF5 0.95, dark green arrow), 90% sensitivity (CDF5 0.10, dark red arrow), accuracy in discriminating
between young CN and cognitively impaired individuals (orange arrow), and accuracy in discriminating between age-matched CN and cognitively impaired
individuals (purple arrow). Accuracy was defined as the point of maximum difference between two CDFs. Amyloid PETwas used in the definition of the cogni-
tively impaired group so only the specificity cut point is shown. For amyloid PET (A), values are shown in both SUVR and centiloid units. (B) tau PET; (C) FDG
PET; and (D) MRI.
C.R. Jack Jr. et al. / Alzheimer’s & Dementia- (2016) 1-12 7when a cut point for amyloid PET based on young people is
applied to elderly normals, an unrealistically high proportion
is labeled abnormal.
Selecting a cut point based on a threshold value beyond
which the rate of change in that biomarker worsens reliably
has high face validity. It is a particularly useful approach for
amyloid because the properties of the biomarker itself are
used to select the cut point, independent from any relationship
to clinical symptoms [46]. The amyloid PET cut point selected
by this reliable worsening method of 1.42 SUVR is similar to
the 1.40 SUVR we used in the past, although we made some
changes to the implementation of the amyloid PET quantita-
tive pipeline. These include no partial volume correction and
a slightly different cerebellar reference ROI. Nonetheless,
our old and new amyloid cut points labeled very similar pro-
portions of the MCSA population as abnormal across all
ages (Supplementary Fig. 2). Using methods described inMurray et al. [14], with our new cut point of 1.42 5/7 (71%)
of autopsied individuals with Thal phase , 2 are labeled
normal, and 23/25 (92%) with Thal phase 2 are labeled
abnormal. Thus, 1.42 SUVR with our new method seems to
be a well determined cut point for amyloid PET.
SUVR values are laboratory specific units that depend on
the tracer used and the methodological implementation of
data processing. The centiloid concept was introduced for
amyloid PET to enable the field to express quantitative am-
yloid PET in universal units [40]. A cut point of 1.42 SUVR
with our current data processing methods corresponds to a
centiloid value of 19.4.2. Approach to tau PET quantification
We selected the entorhinal, amygdala, parahippocampal,
fusiform, inferior temporal, and middle temporal ROIs for
Fig. 4. Biomarkers versus age. Scatter plots of each biomarker versus age among all Mayo Clinic Study of Aging (MCSA) CN individuals with box plots of the
cognitively impaired group shown for reference. The horizontal lines indicate cut points chosen from the fivemethods. The colors used were as follows: reliable
worsening (RW), blue (only in [A]); specificity (Spec.), green; sensitivity (Sens.), red; accuracy of cognitively impaired versus young CN (Acc-Young), orange;
accuracy of cognitively impaired versus matched CN (Acc-Matched), purple. Using each of these five cut point methods, we then label individuals as normal or
abnormal and show the percent abnormal by age as estimated from logistic regression models. For amyloid PET (A), values are shown in both SUVR and cen-
tiloid units. (B) tau PET; (C) FDG PET; and (D) MRI.
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Fig. 5. Distribution of biomarkers in the population. Histograms of the distri-
bution of each biomarker (A–D) among all Mayo Clinic Study of Aging
(MCSA) individuals aged 50–89 years weighted to the Olmsted county popu-
lation by age and sex. The vertical lines indicate cut points chosen from the five
methods. The colors used were as follows: reliable worsening (RW), blue ([A]
only); specificity (Spec.), green; sensitivity (Sens.), red; accuracy of cognitively
impaired versus young CN (Acc-Young), orange; accuracy of cognitively
impaired versus matched CN (Acc-Matched), purple. Systolic blood pressure
is also shown in (E) with the cut point of 140 mmHg (black line). For amyloid
PET (A), values are shown in both SUVR and centiloid units.
C.R. Jack Jr. et al. / Alzheimer’s & Dementia- (2016) 1-12 9our tau meta-ROI because ligand uptake in medial temporal
ROIs is characteristic of clinically normal individuals with
advancing age [27–29,31–34]. Ligand uptake in basal/
lateral temporal lobe—fusiform, inferior temporal, andmiddle temporal—is associated with characteristics of AD
such as abnormal amyloid, worse cognitive performance in
CN individuals, and the clinical diagnosis of MCI or AD
dementia [27–34]. Temporal lobe tau PET uptake also
predicts elevated (abnormal) CSF tau [30,33]. Thus, this
composite set of ROIs captures a broad dynamic range
across the normal to pathologic aging to AD dementia
spectrum [30]. We did not include the hippocampus in the
tau PET meta-ROI because of frequent bleed-in from off-
target uptake in the choroid plexus.
An argument can be made that tau PET should be re-
ported in stages analogously to Braak stage [29,34,47]
rather than using a dichotomous normal/abnormal
designation. However, a tau PET quantification method
based on the magnitude of uptake in an AD-signature com-
posite-ROI that captures a broad diagnostic range, as re-
ported in this study, encapsulates the concept of
pathological severity. Furthermore, most tests used in medi-
cine have some notion of a normal/abnormal cut point in
their continuous distributions, and an effort to accomplish
the same for tau PET seems logical.4.3. Selecting cut points for tau PET, FDG PET, and MRI
For MRI and FDG PET, there was no clear evidence of a
threshold value beyond which rates of hypometabolism or
cortical thinning increase. Thus, the reliable worsening
method did not produce a cut point for FDG PET or MRI
(Fig. 2). As noted above, with no serial data, a reliable wors-
ening cut point for tau PET could not be obtained. Using the
other cut point methods of specificity, sensitivity, and accu-
racy of cognitively impaired versus young CN produced
more lenient cut points, whereas the accuracy of cognitively
impaired versus age-matched CN method produced more
conservative cut points.
The fact that several of the cut point methods produced
very consistent results for tau PET, FDG PET, and MRI
lends support to the validity of these cut points. We empha-
size that regardless of how lenient or conservative a cut
point is, if an individual falls below that cut point for a
particular biomarker, this does not imply that no pathology
is present in the brain. An individual labeled normal may
well have pathology in the brain but not at a sufficient level
to cross the in vivo detection threshold of the biomarker in
question.
The amyloid PET cut points are reported in standardized
centiloid units [40], and the MRI thickness cut points are re-
ported in mm using standard freely available FreeSurfer
methods and thus are usable by other groups. This is not
the case for tau PET and FDG PET cut points because the
specific SUVR values depend on our own imaging process-
ing pipelines. However, for all four modalities, there is value
in comparing results of different methods of selecting cut
points and examining the consequences of applying different
cut points to a clinically normal sample of individuals that
spans a large age range. Different research groups can
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point methods that best suit their own research needs. For
example, cut points from the accuracy of impaired versus
age-matched CN method might be used if the research ques-
tion centered on whether individuals were abnormal relative
to what is expected for age (with the understanding that AD
biomarkers are abnormal in many clinically normal elderly).
In contrast, cut points from the accuracy of impaired versus
young CN method might be used if the research question
centered on whether individuals were abnormal in an abso-
lute sense without accounting for aging effects. The choice
of method could also depend on whether one wants to cap-
ture the earliest stages of disease versus wanting to identify
people who are clearly advanced on the AD pathway.4.4. Dispelling myths about cut points
Examination of the data in Fig. 5 should challenge several
popular assumptions about AD biomarkers. The first is that
amyloid PET (and CSF Ab42) is bimodally distributed in
“the population” [48]. While that is true in highly selected
samples composed mostly of impaired individuals [48], it
is not true in our population-based sample where most are
not demented (Fig. 5). A second assumption is that cut points
for any AD biomarker other than amyloid are not valid
because these biomarkers are not bimodally distributed.
The distribution of systolic blood pressure in Fig. 5 illus-
trates an example of one of many established biomarkers
that is approximately normally distributed and has a cut
point that is widely used clinically.4.5. Group-wise separation
Although our main focus was examining different cut
point methods and the consequences of these different ap-
proaches, Fig. 4 does reveal that the overlap in tau PET
values between elderly CN (over 80) and the impaired group
is considerably less than the overlap present between these
two groups for both FDG PET and MRI. One interpretation
of this is that hypometabolism and atrophy reflect the cumu-
lative effects of brain damage from many possible etiologies
experienced by an individual. In any individual, brain dam-
age may be the product of rapidly progressive active neuro-
degenerative processes, slowly progressive active
neurodegenerative processes, past insults that are now static,
or combinations of these. Aging alone in the absence of
obvious pathology is associated with loss of synapses and
dendrites, loss of function, and neuronal shrinkage [49].
All elderly individuals have experienced the effects of aging
on brain structure and metabolism, and many have experi-
enced or are experiencing other insults as well which ac-
counts for overlap in these measures between clinically
normal elderly and cognitively impaired individuals. In
contrast, tau PET seems to largely index AD-like tau. There-
fore, high-tau levels (especially isocortical tau) appear to beless compatible with preserved cognition than either low
cortical thickness or hypometabolism.4.6. Methodological considerations and limitations
We conditioned the samples used to define many of the
cut points for tau PET, FDG PET, and MRI on amyloid
because our focus was AD centric. This AD centricity
guided our a priori selection of meta-ROIs to include regions
that are characteristically involved in AD: medial-basal tem-
poral atrophy for MRI, medial, basal, and lateral temporal
lobe for tau, and temporal-parietal hypometabolism for
FDG. However, the fact that these brain areas are character-
istic of AD does not make these imaging signatures specific
for AD. Non-AD pathologies like alpha synuclein, TDP 43,
agyrophillic grains, micro infarctions, and so forth can also
result in medial-basal temporal atrophy or temporal-parietal
hypometabolism. Therefore, when applying these cut points
to a general population, individuals both on AD as well as
non-AD–related pathways may be classified as abnormal
on these markers. We have previously labeled these non-
AD related abnormal individuals as suspected non-Alz-
heimer’s pathophysiology [16], an important group that dif-
fers in clinical and cognitive outcomes from those
individuals in the AD pathway.
A limitation of our study was the relatively small number
of young individuals (n 5 49) and cognitively impaired in-
dividuals (n 5 51). To place this in context, however, the
centiloid data set [40] which is the standard by which all
groups are indexing amyloid PET values consists of 34
young controls and 45 AD dementia patients.
Hippocampal volume is widely used in the field; howev-
er, we did not include this measure in our analyses. We have
recently moved away from hippocampal volume as an index
of cumulative neuronal damage and instead now favor the
AD-signature cortical thickness measure, we used in the
article [44]. The primary reason for this is that surface area
and hence also brain volume measures scale with head size
necessitating an adjustment [50]. Correcting for this is not
straightforward because (1) head size is related to sex, (2)
the premorbid relationship between volume and head size
(which cannot be observed in subjects older thanw50) prob-
ably differs by sex, and (3) there are likely to be important
sex-specific causes of atrophy. Although we hope to investi-
gate how to optimally account for the confounding without
introducing artifactual differences due to over adjustment,
a very straightforward solution is to use a measure of cortical
thickness which does not scale closely with head size and
does not require any adjustment.Acknowledgments
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1. Systematic review: The authors reviewed the litera-
ture using traditional (e.g., PubMed) sources and
meeting abstracts and presentations.
2. Interpretation: We have identified a single cut point
for amyloid PET (SUVR 1.42, centiloid 19) and
both lenient and conservative cut points for tau
PET, FDG PET and MRI based on principled ap-
proaches. To optimize consistency in approach, our
future plan is to base lenient cut points for tau PET,
FDG PET, and cortical thickness on the cognitively
impaired versus young CN method (1.23 SUVR for
tau PET, 1.56 SUVR for FDG PET; and 2.67 mm
for cortical thickness) and to base conservative cut
points on the cognitively impaired versus age-
matched CN method (1.33 SUVR for tau PET, 1.41
SUVR for FDG PET, and 2.57 mm for cortical
thickness).
3. Future directions: We outline a principled approach
to selecting biomarker cut points that can aid the
development of diagnostic criteria that hinge on
biomarker results.
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